MX2021002710A - Anticuerpos anti-c5 humanizados y usos de los mismos. - Google Patents

Anticuerpos anti-c5 humanizados y usos de los mismos.

Info

Publication number
MX2021002710A
MX2021002710A MX2021002710A MX2021002710A MX2021002710A MX 2021002710 A MX2021002710 A MX 2021002710A MX 2021002710 A MX2021002710 A MX 2021002710A MX 2021002710 A MX2021002710 A MX 2021002710A MX 2021002710 A MX2021002710 A MX 2021002710A
Authority
MX
Mexico
Prior art keywords
antibodies
humanized anti
complement
antibody
individual
Prior art date
Application number
MX2021002710A
Other languages
English (en)
Inventor
Ping Tsui
Wenchao Song
Sayaka Sato
Takashi Miwa
Damodar Gullipalli
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2021002710A publication Critical patent/MX2021002710A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0393Animal model comprising a reporter system for screening tests
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/859Animal models comprising reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se refiere a la inhibición de la señalización del complemento utilizando un anticuerpo anti-C5; específicamente, la invención se refiere a métodos para tratar una enfermedad mediada por el complemento o un trastorno mediado por el complemento en un individuo al poner en contacto al individuo con un anticuerpo anti-C5.
MX2021002710A 2018-09-06 2019-09-06 Anticuerpos anti-c5 humanizados y usos de los mismos. MX2021002710A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727666P 2018-09-06 2018-09-06
US201962837833P 2019-04-24 2019-04-24
PCT/US2019/049890 WO2020051418A1 (en) 2018-09-06 2019-09-06 Humanized anti-c5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021002710A true MX2021002710A (es) 2021-09-23

Family

ID=69723287

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002710A MX2021002710A (es) 2018-09-06 2019-09-06 Anticuerpos anti-c5 humanizados y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220177556A1 (es)
EP (1) EP3846850A4 (es)
JP (1) JP2021536509A (es)
KR (1) KR20210055742A (es)
CN (1) CN113038967A (es)
AU (1) AU2019336214A1 (es)
BR (1) BR112021004141A2 (es)
CA (1) CA3111396A1 (es)
IL (1) IL281272A (es)
MX (1) MX2021002710A (es)
SG (1) SG11202101853PA (es)
WO (1) WO2020051418A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11578137B2 (en) * 2017-03-06 2023-02-14 The Trustees Of The University Of Pennsylvania Anti-C5 antibodies and uses thereof
CA3137907A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
WO2024097441A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024097796A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
WO2014160958A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
UA126561C2 (uk) * 2016-06-17 2022-11-02 Чугаі Сейяку Кабусікі Кайся Застосування антитіла проти с5
US11578137B2 (en) * 2017-03-06 2023-02-14 The Trustees Of The University Of Pennsylvania Anti-C5 antibodies and uses thereof
CA3137907A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof

Also Published As

Publication number Publication date
CN113038967A (zh) 2021-06-25
EP3846850A4 (en) 2022-06-15
CA3111396A1 (en) 2020-03-12
EP3846850A1 (en) 2021-07-14
SG11202101853PA (en) 2021-03-30
BR112021004141A2 (pt) 2021-05-25
IL281272A (en) 2021-04-29
WO2020051418A1 (en) 2020-03-12
JP2021536509A (ja) 2021-12-27
AU2019336214A1 (en) 2021-04-29
KR20210055742A (ko) 2021-05-17
US20220177556A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
ZA201905866B (en) Anti-c5 antibodies and uses thereof
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
NZ736728A (en) Cd123 antibodies and conjugates thereof
EA201890175A1 (ru) Антитела к cd40
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2021012997A (es) Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MX2020008030A (es) Anticuerpos de glipicano 3 y conjugados de los mismos.
EA201992756A2 (ru) Антитела против cd48 и их конъюгаты
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
CU24556B1 (es) Anticuerpos anti-basigin humanizados
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
PH12016501579B1 (en) Novel anti-presepsin antibody
AR112563A1 (es) Anticuerpos monoclonales anti-sortilina útiles en la corrección de un nivel deficiente de progranulina (pgrn)
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
MX2020010092A (es) Variantes de anticuerpo c-terminales.